Role of chemotherapy in relapsed ovarian cancer-Reference-Cited by-同舟云学术

Role of chemotherapy in relapsed ovarian cancer

Published:1999-12 Issue:3 Volume:32 Page:221-228
ISSN:1040-8428
Container-title:Critical Reviews in Oncology/Hematology
language:
Short-container-title:

Author:

Colombo N

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference54 articles.

1. Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a gynecologic oncology group study;Thigpen;J. Clin. Oncol.,1994

2. Paclitaxel for platinum-refractory ovarian cancer: results from the first 1000 patients registered to National Cancer Institute treatment referral center 9103;Trimble;J. Clin. Oncol.,1993

3. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms;McGuire;Ann. Intern. Med.,1989

4. Phase II study and long-term follow-up of patients treated with taxol for advanced ovarian adenocarcinoma;Einzig;J. Clin. Oncol.,1992

5. A phase II multicenter non-randomized study of Taxol (paclitaxel) in patients with ovarian cancer previously treated with platinum therapy;Salmi;Acta Obstet. Gynecol. Scand.,1994

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Weekly AUC2 carboplatin in acquired platinum-resistant ovarian cancer with or without oral phenoxodiol, a sensitizer of platinum cytotoxicity: the phase III OVATURE multicenter randomized study;Annals of Oncology;2014-01

2. Gemcitabine and Vinorelbine Combination in Platinum-Sensitive Recurrent Ovarian Cancer;International Journal of Gynecologic Cancer;2009-11

3. Is There a Taxane-Free Interval That Predicts Response to Taxanes as a Later-Line Treatment of Recurrent Ovarian or Primary Peritoneal Cancer?;International Journal of Gynecologic Cancer;2009-03

4. Effect of paclitaxel on vascular endothelial growth factor (VEGF) and interleukin (IL)-8 in serum of patients with recurrent ovarian cancer: a comparison of weekly vs triweekly regimens;Targeted Oncology;2006-04

5. A phase II study of pegylated liposomal doxorubicin oxaliplatin and cyclophosphamide as second-line treatment in relapsed ovarian carcinoma;International Journal of Gynecological Cancer;2006-02